Language：Japanese   Publisher：(公社)日本婦人科腫瘍学会  

researchmap

Language：Japanese   Publisher：(公社)日本婦人科腫瘍学会  

researchmap

Language：Japanese   Publisher：中国四国産科婦人科学会  

researchmap

Language：Japanese   Publisher：中国四国産科婦人科学会  

researchmap

Language：Japanese   Publisher：中国四国産科婦人科学会  

researchmap

Language：Japanese   Publisher：(公社)日本産科婦人科学会  

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

BACKGROUND: Gynecologic cancers are one of the most common types of malignancies in working-age women. We aimed to determine the factors that impede women from returning to the same workplace after treatment for such cancers. METHODS: A questionnaire-based survey was conducted on 194 women who underwent treatment for gynecologic cancer at the Okayama University (≥1 year after cancer treatment and <65 years of age). We performed a logistic regression analysis to determine the relationship between returning to the same workplace and not taking sick leave. RESULTS: The median age at diagnosis was 49.0 years, and the median time from cancer treatment to questionnaire completion was 3.8 years. Not returning to the same workplace was positively associated with not being regularly employed (P = 0.018), short work time per day (P = 0.023), low personal income (P = 0.004), not taking sick leave (P < 0.001), advanced cancer stage (P = 0.018) and long treatment time (P = 0.032). Interestingly, not taking sick leave was strongly associated with not returning to the same workplace in the multivariable analysis (P < 0.001). CONCLUSIONS: Not taking sick leave likely was negatively associated with returning to the same workplace after the treatment for gynecologic cancer. Therefore, we suggest that steps be taken to formally introduce a sick leave system over and above the paid leave system in Japan.

DOI： 10.1093/jjco/hyad159

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

OBJECTIVE: To investigate whether maintenance treatment could be safely and effectively performed with olaparib, olaparib plus bevacizumab and niraparib in platinum-sensitive advanced ovarian cancer at multiple institutions in Japan. METHODS: We investigated progression-free survival and adverse events in 117 patients with platinum-sensitive advanced ovarian cancer treated with maintenance therapy. RESULTS: The median progression-free survival of 117 patients was 20.1 months. Patients with germline BRCA pathogenic variants had a significantly better prognosis than the other groups (P < 0.001). Furthermore, in the multivariate analysis, stage IV (P = 0.016) and germline BRCA wild-type (P ≤ 0.001) were significantly associated with worse progression-free survival in patients with advanced ovarian cancer. Regarding adverse events, all three types of maintenance treatment were significantly worse than chemotherapy given before maintenance treatment with respect to renal function (olaparib, P = 0.037; olaparib plus bevacizumab, P < 0.001; and niraparib, P = 0.016). CONCLUSION: Maintenance treatment was performed effectively and safely. Renal function deterioration is likely to occur during maintenance treatment, and careful administration is important in platinum-sensitive advanced ovarian cancer.

DOI： 10.1093/jjco/hyad125

PubMed

researchmap

Language：Japanese   Publisher：中国四国産科婦人科学会  

researchmap

Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

BACKGROUND/AIM: To determine if maintenance treatment can be performed effectively and safely in patients with platinum-sensitive relapsed ovarian cancer. PATIENTS AND METHODS: We carried out a multi-center study to investigate progression-free survival (PFS) and adverse events (AEs) in 229 patients receiving maintenance treatment for platinum-sensitive relapsed ovarian cancer. RESULTS: The median PFS in the 229 patients with maintenance treatment was 14.0 months (95% confidence interval=10.3-17.6 months). The hematological toxicities included ≥grade 3 anemia in 33.2% of cases. Anemia during maintenance treatment was significantly more common than anemia during chemotherapy given before maintenance treatment (p<0.001). Anemia during chemotherapy prior to maintenance treatment significantly increased the risk of anemia during maintenance treatment, compared with other clinical features (p<0.001). CONCLUSION: Maintenance treatment can be performed safely and effectively in patients with platinum-sensitive relapsed ovarian cancer. Anemia during chemotherapy given before maintenance treatment significantly increased the risk of developing anemia during maintenance treatment in patients with platinum-sensitive relapsed ovarian cancer.

DOI： 10.21873/anticanres.16546

PubMed

researchmap

Language：English  

The abscopal effect is a rare phenomenon, in which tumor shrinkage in the nonirradiated metastatic region is observed after radiotherapy. Certainly, this response is sometimes reported with the combined use of immune-checkpoint inhibitors, but a pure abscopal effect is extremely rare, especially in endometrial cancer. We present the case of a 79-year-old woman with an advanced endometrial carcinosarcoma. She was treated with surgical reduction of the primary lesion, followed by radiotherapy of the metastatic regional lymph nodes. Distant metastases were detected in radiological imaging test 2 months after the completion of radiotherapy, and we carefully followed up without any treatment considering the patient's tolerability for further procedures. Six months after recurrence, she experienced cytoreduction in the metastatic lesions confirmed through imaging findings, which was believed to be an abscopal effect, and maintained this shrinking state for 15 months. Herein, we describe this pure abscopal effect from the perspective of imaging, pathological and molecular findings, and therapeutic strategies.

DOI： 10.1016/j.radcr.2023.04.031

PubMed

researchmap

Language：Japanese   Publisher：(公社)日本婦人科腫瘍学会  

researchmap

Language：Japanese   Publisher：(公社)日本婦人科腫瘍学会  

researchmap

Language：Japanese   Publisher：中国四国産科婦人科学会  

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Adenosine deaminase acting on RNA 1 (ADAR1), a recently described epigenetic modifier, is believed to play a critical oncogenic role in human cancers. However, its functional role and clinical significance in cervical cancer (CC) remain unclear. ADAR1 knockdown was performed to investigate its oncogenic functions in SiHa (HPV16), HeLa (HPV18), and Yumoto (non-HPV) CC cell lines. Cytoplasmic and nuclear ADAR1 expression were examined to clarify their correlation with clinicopathological parameters and prognosis in patients with CC. This resulted in increased apoptosis and necroptosis in HPV16 -type SiHa, HPV18-type HeLa, and non-HPV-type Yumoto CC cell lines. Progression-free survival (PFS) rates of patients exhibiting high cytoplasmic and nuclear ADAR1 expression were poorer than those in the other groups (P = 0.016). Multivariate analysis indicated that the combination of higher cytoplasmic and nuclear ADAR1 expression was an independent predictor of prognosis in patients with CC (P = 0.017). ADAR1 could be a potential therapeutic target for HPV-positive or HPV-negative CC. The combination of cytoplasmic and nuclear ADAR1 comprises a better prognostic factor for CC.

DOI： 10.1038/s41598-023-30452-y

PubMed

researchmap

Language：Japanese   Publisher：(公社)日本産科婦人科学会  

researchmap

Language：Japanese   Publisher：(公社)日本産科婦人科学会  

researchmap

Language：Japanese   Publisher：(公社)日本産科婦人科学会  

researchmap

Language：Japanese   Publisher：中国四国産科婦人科学会  

researchmap

Other Link： https://search.jamas.or.jp/default/link?pub_year=2022&ichushi_jid=J05038&link_issn=&doc_id=20221221480020&doc_link_id=%2Fcv0mtrob%2F2022%2F007101%2F020%2F0117-0121%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fcv0mtrob%2F2022%2F007101%2F020%2F0117-0121%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

Language：Japanese   Publisher：中国四国産科婦人科学会  

researchmap

Other Link： https://search.jamas.or.jp/default/link?pub_year=2022&ichushi_jid=J05038&link_issn=&doc_id=20221221480017&doc_link_id=%2Fcv0mtrob%2F2022%2F007101%2F017%2F0099-0103%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fcv0mtrob%2F2022%2F007101%2F017%2F0099-0103%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

Language：Japanese   Publisher：中国四国産科婦人科学会  

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

OBJECTIVE: Adenosine-to-inosine (A-to-I) RNA editing is a recently described epigenetic modification, which is believed to constitute a key oncogenic mechanism in human cancers. However, its functional role and clinical significance in endometrial cancer (EC) remain unclear. METHODS: Adenosine Deaminase family Acting on RNA1 (ADAR1) expression and Antizyme inhibitor 1 (AZIN1) RNA editing were examined to clarify the correlation with clinicopathological parameters and prognosis in EC patients. The biological functions and inhibitory effects of ADAR1 knockdown were investigated in JHUCS-1 and TU-ECS-1 EC cell lines. RESULTS: ADAR1 showed significant association with worse histology (P = 0.006), and lymph vascular space involvement (P = 0.049) in EC. The level of AZIN1 RNA editing was also significantly associated with worse histology (P = 0.012). ADAR1 expression was significantly correlated with AZIN1 RNA editing level (R = 0.729, R2 = 0.547, P < 0.001). Multivariate analysis indicated that higher ADAR1 expression along with AZIN1 RNA editing is an independent predictor of prognosis in EC patients (P = 0.015). Knockdown of ADAR1 led to increased MDA-5, RIG-I, PKR, and IRF-7 expression, which in turn resulted in increased levels of Bak and apoptosis in EC cells. CONCLUSIONS: High ADAR1 expression along with AZIN1 RNA editing could be a predictor of worse prognosis in EC. ADAR1 could be a potential therapeutic target in EC patients.

DOI： 10.1016/j.ygyno.2022.05.026

PubMed

researchmap

Language：Japanese   Publisher：(公社)日本婦人科腫瘍学会  

researchmap

Language：Japanese   Publisher：(公社)日本婦人科腫瘍学会  

researchmap

Language：Japanese   Publisher：(公社)日本婦人科腫瘍学会  

researchmap

Language：Japanese   Publisher：中国四国産科婦人科学会  

researchmap

Language：Japanese   Publisher：中国四国産科婦人科学会  

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Cancer patients have increased risk of venous thromboembolism (VTE) that must be assessed before treatment. This study aimed to determine effective VTE biomarkers in gynecologic cancer (GC). We investigated the correlation between D-dimer levels, Khorana risk score (KRS), Glasgow prognostic score (GPS), and VTE in 1499 GC patients (583 cervical cancer (CC), 621 endometrial cancer (EC), and 295 ovarian cancer (OC) patients) treated at our institution between January 2008 and December 2019. χ2 and Mann-Whitney U-tests were used to determine statistical significance. We used receiver operating characteristic-curve analysis to evaluate the discriminatory ability of each parameter. D-dimer levels were significantly correlated with KRS and GPS in patients with GC. VTE was diagnosed in 11 CC (1.9%), 27 EC (4.3%), and 39 OC patients (13.2%). Optimal D-dimer cut-off values for VTE were 3.1, 3.2, and 3.9 μg/ml in CC, EC and OC patients, respectively. D-dimer could significantly predict VTE in all GC patients. Furthermore, D-dimer combined with GPS was more accurate in predicting VTE than other VTE biomarkers in stage IIIC and IVA OC (AUC: 0.846; p<0.001). This study demonstrates that combined D-dimer and GPS are useful in predicting VTE in patients with OC.

DOI： 10.18926/AMO/63406

PubMed

researchmap

Language：Japanese   Publisher：(公社)日本産科婦人科学会  

researchmap

Language：Japanese   Publisher：(公社)日本産科婦人科学会  

researchmap

Language：Japanese   Publisher：(公社)日本産科婦人科学会  

researchmap

Language：Japanese   Publisher：(公社)日本産科婦人科学会  

researchmap

Language：Japanese   Publisher：(公社)日本産科婦人科学会  

researchmap

Language：Japanese   Publisher：(公社)日本産科婦人科学会  

researchmap

Language：Japanese   Publisher：(公社)日本産科婦人科学会  

researchmap

Language：Japanese   Publisher：(公社)日本産科婦人科学会  

researchmap

Language：Japanese   Publisher：(公社)日本産科婦人科学会  

researchmap

Language：Japanese   Publisher：(公社)日本産科婦人科学会  

researchmap

Language：Japanese   Publisher：(公社)日本産科婦人科学会  

researchmap

Language：Japanese   Publisher：(公社)日本産科婦人科学会  

researchmap

Language：Japanese   Publisher：(公社)日本産科婦人科学会  

researchmap

Language：Japanese   Publisher：(公社)日本産科婦人科学会  

researchmap

Language：Japanese   Publisher：中国四国産科婦人科学会  

researchmap

Other Link： https://search-tp.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2021&ichushi_jid=J05038&link_issn=&doc_id=20211220410009&doc_link_id=%2Fcv0mtrob%2F2021%2F007001%2F009%2F0049-0052%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fcv0mtrob%2F2021%2F007001%2F009%2F0049-0052%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

Language：Japanese   Publisher：中国四国産科婦人科学会  

researchmap

Other Link： https://search-tp.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2021&ichushi_jid=J05038&link_issn=&doc_id=20211220410038&doc_link_id=%2Fcv0mtrob%2F2021%2F007001%2F038%2F0209-0213%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fcv0mtrob%2F2021%2F007001%2F038%2F0209-0213%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

Language：Japanese   Publisher：中国四国産科婦人科学会  

researchmap

Other Link： https://search-tp.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2021&ichushi_jid=J05038&link_issn=&doc_id=20211220410015&doc_link_id=%2Fcv0mtrob%2F2021%2F007001%2F015%2F0081-0085%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fcv0mtrob%2F2021%2F007001%2F015%2F0081-0085%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

Language：Japanese   Publisher：中国四国産科婦人科学会  

researchmap

Language：Japanese   Publisher：(一社)日本産科婦人科内視鏡学会  

researchmap

Language：Japanese   Publisher：中国四国産科婦人科学会  

researchmap

Language：Japanese   Publisher：(一社)日本産科婦人科内視鏡学会  

researchmap

Language：Japanese   Publisher：(一社)日本産科婦人科内視鏡学会  

researchmap

Language：Japanese   Publisher：中国四国産科婦人科学会  

researchmap

Language：Japanese   Publisher：中国四国産科婦人科学会  

researchmap

Language：Japanese   Publisher：中国四国産科婦人科学会  

researchmap

Language：Japanese   Publisher：中国四国産科婦人科学会  

researchmap

Language：Japanese   Publisher：中国四国産科婦人科学会  

researchmap

Language：Japanese   Publisher：中国四国産科婦人科学会  

researchmap

Language：Japanese   Publisher：(公社)日本婦人科腫瘍学会  

researchmap

Language：Japanese   Publisher：(公社)日本婦人科腫瘍学会  

researchmap

Language：Japanese   Publisher：(公社)日本婦人科腫瘍学会  

researchmap

Language：English  

Acute promyelocytic leukemia (APL) is a hematological emergency that requires urgent intervention because of the high incidence of early hemorrhagic death. When patients with APL experience a synchronous solid organ tumor, the tumor's treatment must also be done properly. Differentiation-inducing therapy using arsenic trioxide (ATO) has less hematological toxicity compared to cytotoxic chemotherapy and might be preferable for untreated APL patients with a synchronous solid organ tumor. Here we describe the first successful case of untreated APL and synchronous endometrial cancer (in an adult Japanese woman) treated with ATO consolidation therapy and the subsequent surgery and chemotherapy for endometrial cancer.

DOI： 10.18926/AMO/61904

PubMed

researchmap

Language：Japanese   Publisher：(公社)日本産科婦人科学会  

researchmap

Language：Japanese   Publisher：(公社)日本産科婦人科学会  

researchmap

Language：Japanese   Publisher：(公社)日本産科婦人科学会  

researchmap

Language：Japanese   Publisher：(公社)日本産科婦人科学会  

researchmap

Language：Japanese   Publisher：(公社)日本産科婦人科学会  

researchmap

Language：Japanese   Publisher：(公社)日本産科婦人科学会  

researchmap

Language：Japanese   Publisher：(公社)日本婦人科腫瘍学会  

researchmap

Language：Japanese   Publisher：(公社)日本婦人科腫瘍学会  

researchmap

Language：Japanese   Publisher：(公社)日本婦人科腫瘍学会  

researchmap

Language：Japanese   Publisher：(公社)日本婦人科腫瘍学会  

researchmap

Language：Japanese   Publisher：中国四国産科婦人科学会  

researchmap

Other Link： https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2020&ichushi_jid=J05038&link_issn=&doc_id=20201214470003&doc_link_id=%2Fcv0mtrob%2F2020%2F006901%2F003%2F0011-0017%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fcv0mtrob%2F2020%2F006901%2F003%2F0011-0017%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

Language：Japanese   Publisher：(一社)日本産科婦人科内視鏡学会  

researchmap

Language：Japanese   Publisher：(一社)日本産科婦人科内視鏡学会  

researchmap

Language：Japanese   Publisher：(株)メジカルビュー社  

researchmap

Language：Japanese   Publisher：中国四国産科婦人科学会  

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

This study aimed to determine whether the risk conferred by gynecologic cancer (GC) as second primary cancer (SPC) differs from that associated with GC as first primary cancer (FPC). We investigated the correlations between FPC/SPC and the characteristics and prognoses of 1,645 GC patients (701 with cervical cancer [CC], 641 with endometrial cancer [EM], and 303 with ovarian cancer [OV]). The χ2 test and the Kaplan-Meier method were used to determine whether FPC/SPC and the characteristics and prognoses of GC patients. Of the SPC patients, 26 (3.7%) had CC, 53 (8.3%) had EM, and 31 (10.2%) had OV. The most common previous cancer type in SPC of GC patients was breast cancer, which was observed in 13 patients (50.0%) with CC, 23 (43.4%) with EM, and 16 (51.6%) with OV. In all patients with CC, EM, and OV as SPC, the stage was significantly associated with recurrence. There were no significant differences in the morbidity or mortality of CC, EM, or OV patients between those with FPC and those with SPC. The risk of SPC development in GC patients varied, ranging from 3.5% (CC) to 10.3% (OV) of patients.

DOI： 10.18926/AMO/58268

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

The aim of the present study was to determine whether chronic diseases (CD), such as hypertension, diabetes mellitus, dyslipidemia, heart diseases and cerebrovascular diseases, are occurrence risk factors and affect the survival of patients with gynecological cancers (GC). The correlations between CD and the characteristics and survival of 1,590 GC patients [685 with cervical cancer (CC), 613 with endometrial cancer (EM) and 292 with ovarian cancer (OV)] were investigated in the present study. Of the CD patients, 189 had CC (27.6%), 265 had EM (43.2%) and 72 had OV (24.7%). The incidence of CD increased with age in GC patients. The number of CD patients aged ≥70 years, was 8.6-fold higher in the CC group, 3.0-fold higher in the EM group, and 9.6-fold higher in the OV group compared with those aged <50 years. CD and excess body weight were associated with GC regardless of patient age. However, there was no correlation between CD and survival at any age in GC patients. These findings indicate that CD contribute to >24% of the occurrence risk factors in GC patients in Japan.

DOI： 10.3892/mco.2020.1989

PubMed

researchmap

Language：Japanese   Publisher：(公社)日本産科婦人科学会  

researchmap

Language：Japanese   Publisher：(公社)日本産科婦人科学会  

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Low skeletal muscle mass (sarcopenia) is an important prognostic risk factor for the outcome of a variety of cancer types. The current study investigated whether skeletal muscle area (SMA), psoas area (PA) and psoas major volume (PV) are associated with progression-free survival (PFS) and overall survival (OS) in patients with epithelial ovarian cancer (OC). A total of 92 OC patients were enrolled in the present study. Pre-treatment with SMA and PA was assessed using computed tomography (CT) and PV was calculated using a three-dimensional-CT (3D-CT). The clinical factors associated with sarcopenia and prognosis were retrospectively evaluated. For all patients, the median PFS and OS were 19 and 32 months, respectively. Patients exhibiting lower PV (<195.6 cm3) had significantly poorer PFS and OS compared with patients exhibiting higher PV (≥195.6 cm3; P=0.018 and P=0.006), while those with low SMA (<92.92 cm2) had significantly worse OS than patients with higher SMA (≥92.92 cm2; P=0.030). PV was also demonstrated to be superior to SMA and PA in prognosis prediction. PV by 3D-CT can serve as an indicator of poor prognosis in patients with OC.

DOI： 10.3892/mco.2019.1912

PubMed

researchmap

Language：Japanese   Publisher：中国四国産科婦人科学会  

researchmap

Language：Japanese   Publisher：(一社)日本産科婦人科内視鏡学会  

researchmap

Language：Japanese   Publisher：(公社)日本婦人科腫瘍学会  

researchmap

Language：Japanese   Publisher：(公社)日本婦人科腫瘍学会  

researchmap

Language：Japanese   Publisher：中国四国産科婦人科学会  

researchmap

Language：Japanese   Publisher：(公社)日本婦人科腫瘍学会  

researchmap

Language：Japanese   Publisher：(公社)日本婦人科腫瘍学会  

researchmap

Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)   Publisher：Anticancer Research USA Inc.  

BACKGROUND/AIM: The objective of this study was to determine if sarcopenia was a predictor of poor prognosis in patients with cervical cancer (CC) undergoing concurrent chemoradiation therapy (CCRT) or radiation therapy (RT). MATERIALS AND METHODS: A total of 236 patients with CC undergoing CCRT or RT were retrospectively examined. We determined if clinical characteristics and survival were correlated with pretreatment sarcopenia, measured as psoas muscle index (PI) or skeletal muscle index (SMI). RESULTS: Pretreatment PI and SMI were related to parametrial involvement with CC undergoing CCRT or RT (p=0.002, and, p=0.034, respectively). The median progression-free survival (PFS) and overall survival (OS) times in patients undergoing CCRT or RT were 29.0 and 34.5 months, respectively. Neither PI nor SMI were prognostic predictors in patients with CC undergoing CCRT or RT. CONCLUSION: Sarcopenia is not a predictive factor of outcome in patients with CC undergoing CCRT or RT.

DOI： 10.21873/anticanres.13196

PubMed

researchmap

Language：Japanese   Publisher：(公社)日本産科婦人科学会  

researchmap

Language：Japanese   Publisher：(公社)日本産科婦人科学会  

researchmap

Language：Japanese   Publisher：(公社)日本産科婦人科学会  

researchmap

Language：Japanese   Publisher：(一社)日本女性医学学会  

researchmap

Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)   Publisher：BMJ  

<sec><title>Objective</title>The aim of this observational study was to investigate correlations between long-term chemotherapy-induced peripheral neurotoxicity (CIPN) and quality of life (physical well-being, social well-being, emotional well-being, and functional well-being [FWB]) among survivors of gynecologic cancer (GC).

</sec><sec><title>Methods</title>We aimed to assess the correlation of quality of life and long-term CIPN with the temporal change in recurrence-free GC survival. Questionnaire responses and clinical data of 259 GC survivors were collected and assessed according to treatment received. The χ² test was used to determine the significance of correlations.

</sec><sec><title>Results</title>Of 165 evaluable patients treated by chemotherapy, 36 patients (21.8%) developed CIPN of Common Toxicity Criteria for Adverse Events grade 1 or higher during the study. Chemotherapy-induced peripheral neurotoxicity had significantly improved over time in the domain of FWB at 61 months or more after the end of chemotherapy (posttreatment 4) among GC survivors (<italic>P</italic> = 0.003). Furthermore, CIPN treated by more than 6 courses of the paclitaxel and carboplatin regimen among GC survivors showed significant improvement over time in the emotional well-being domain at 25 to 60 months and 61 months or more after the end of chemotherapy (posttreatments 3 and 4) (<italic>P</italic> = 0.037 and <italic>P</italic> = 0.023) and in FWB at posttreatment 4 (<italic>P</italic> &lt; 0.001).

</sec><sec><title>Conclusions</title>Emotional and functional domains of CIPN improved over time among GC survivors treated by more than 6 courses of the paclitaxel and carboplatin regimen. Based on these results, further research is required to identify additional preventative or curative approaches.

</sec>

DOI： 10.1097/igc.0000000000001320

PubMed

researchmap

Language：Japanese   Publisher：(一社)日本産科婦人科内視鏡学会  

researchmap

Language：Japanese   Publisher：中国四国産科婦人科学会  

researchmap

Other Link： https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2017&ichushi_jid=J05038&link_issn=&doc_id=20170612460016&doc_link_id=%2Fcv0mtrob%2F2016%2F006502%2F016%2F0217-0221%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fcv0mtrob%2F2016%2F006502%2F016%2F0217-0221%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

Language：Japanese   Publisher：(一社)日本生殖医学会  

researchmap

Language：Japanese   Publisher：(公社)日本産科婦人科学会  

researchmap

Language：Japanese   Publisher：(一社)日本糖尿病・妊娠学会  

researchmap

Language：Japanese   Publisher：中国四国産科婦人科学会  

researchmap

Other Link： https://search-tp.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2015&ichushi_jid=J05038&link_issn=&doc_id=20150709460024&doc_link_id=%2Fcv0mtrob%2F2014%2F006302%2F024%2F0299-0303%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fcv0mtrob%2F2014%2F006302%2F024%2F0299-0303%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

Language：Japanese   Publisher：中国四国産科婦人科学会  

researchmap

Other Link： https://search-tp.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2014&ichushi_jid=J05038&link_issn=&doc_id=20141216480013&doc_link_id=%2Fcv0mtrob%2F2014%2F006301%2F013%2F0059-0062%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fcv0mtrob%2F2014%2F006301%2F013%2F0059-0062%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

Language：Japanese   Publisher：中国四国産科婦人科学会  

researchmap

Other Link： https://search-tp.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2014&ichushi_jid=J05038&link_issn=&doc_id=20141216480023&doc_link_id=%2Fcv0mtrob%2F2014%2F006301%2F023%2F0111-0115%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fcv0mtrob%2F2014%2F006301%2F023%2F0111-0115%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

Language：Japanese   Publisher：中国四国産科婦人科学会  

researchmap

Other Link： https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2014&ichushi_jid=J05038&link_issn=&doc_id=20140620430022&doc_link_id=%2Fcv0mtrob%2F2013%2F006202%2F022%2F0263-0267%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fcv0mtrob%2F2013%2F006202%2F022%2F0263-0267%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

Language：Japanese   Publisher：(公社)日本婦人科腫瘍学会  

researchmap

Language：Japanese   Publisher：(公社)日本婦人科腫瘍学会  

researchmap

Language：Japanese   Publisher：(公社)日本婦人科腫瘍学会  

researchmap

Language：Japanese   Publisher：(公社)日本婦人科腫瘍学会  

researchmap

Language：Japanese   Publisher：(公社)日本婦人科腫瘍学会  

researchmap

Language：Japanese   Publisher：(公社)日本婦人科腫瘍学会  

researchmap

Language：Japanese   Publisher：(公社)日本産科婦人科学会  

researchmap

Language：Japanese   Publisher：(公社)日本産科婦人科学会  

researchmap

Language：Japanese   Publisher：(公社)日本産科婦人科学会  

researchmap

Language：Japanese   Publisher：(公社)日本産科婦人科学会  

researchmap

Language：Japanese   Publisher：(公社)日本産科婦人科学会  

researchmap

Language：Japanese   Publisher：(公社)日本産科婦人科学会  

researchmap

Language：Japanese   Publisher：(株)メジカルビュー社  

researchmap

Language：Japanese   Publisher：(一社)日本女性医学学会  

researchmap

Language：Japanese   Publisher：(一社)日本生殖医学会  

researchmap

Language：Japanese   Publisher：[広島] : 日本産科婦人科学会中国四国合同地方部会  

CiNii Article

CiNii Books

researchmap

Other Link： http://id.ndl.go.jp/bib/028308706